Skip to main content

Talk Bio

Search This Blog

AbbVie's Skyrizi retakes edge in pharma's July ad spending league

on August 07, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

AbbVie's Skyrizi retakes edge in pharma's July ad spending league.

Skyrizi topped the list as the biggest pharma drug ad spender in July, with an estimated national TV ad spend of $23.2 million.

Overall spending on TV drug ads fell sharply in July to $126.3 million from $163.2 million in June, marked by significant declines compared to earlier in the year.

Skyrizi's dominance is part of a broader trend where AbbVie continues to lead the annual TV drug ad spending rankings, with Skyrizi as the top brand for the third consecutive year.

Sources:

AbbVie's Skyrizi, Rinvoq retake the top TV drug ad spenders' crown as top climber Rexulti continues strong run

Skyrizi Tops July's Pharma Rankings — and What It Means for ...

AbbVie's Skyrizi stays king of the drug ad spenders as total spending plummets

July's Top Rx Brands by TV Ad Spend - The Measure

TV drug ad spending plummeted in July, while AbbVie's Skyrizi regained ...

Skyrizi soars to top of Rx, OTC pharma brand rankings in July

AbbVie launches new Skyrizi commercial after topping TV drug ad spenders’ ranking in July

J&J's Tremfya remains on top in Q2 pharma ad spending league as overall outlay drops

TV drug ad spending plummeted in July, while AbbVie's Skyrizi regained ...

Drug Named Top U.S. TV Ad Spender for 2025 | News

AbbVie's Skyrizi, Novo's Wegovy duke it out in Q2 TV ad spending totals

J&J's Tremfya retakes ad spending top spot in June

AbbVie's Skyrizi was the top TV drug ad spender for the full year again ...

AbbVie pulls off a hat trick with 3rd straight year as top TV drug ad… | James Carpenter

AbbVie ad spending Dupixent impression (attitude) July league pharma marketing Rinvoq Skyrizi SOV Television Tremfya TV drug

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Powered by Blogger

X-Data LLC